Medasense Announces Compatibility with Philips IntelliVue Patient Monitors

Ramat Gan, Israel (ots/PRNewswire) -

Medasense Biometrics Ltd., developer of the physiological
pain-response monitoring technology (NOL® -- the Nociception Level
Index), now supports Philips IntelliVue Patient Monitors for
anesthesia and critical care monitoring.

(Photo:
https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg
)

Commercially available in Europe, Canada, and Australia,
Medasense's PMD-200(TM) monitor and its NOL index, help clinicians to
optimise patient's pain management by monitoring the nociceptive
(pain response) state in situations where patients are unable to
communicate, especially in surgery under general anaesthesia and in
critical care. A recent positive outcome study demonstrated reduced
opioid-consumption and improved hemodynamic stability in patients
undergoing major surgery guided by the NOL technology.

The new PMD-200 SW (1.0.0.29) is compatible with a wide range of
Philips IntelliVue Patient Monitors throughout the Philips
EC10IntelliBridge Open Interface driver and the EC5 ID Module #104.
Technology connectivity enables clinicians to have a reliable,
consolidated view of changes in pain response (nociception) level,
integrated within their vital sign monitor and saved into their
electronical medical record (EMR).

Galit Zuckerman-Stark, Medasense CEO and founder said: "With the
clinical community long considering pain assessment as an important
measurement of patient wellbeing, this cooperation marks new ground
in making NOL the new standard of care for pain-response
monitoring. We will continue our innovative developments and
collaborations with industry leaders such as Philips, to make our
technology available to as many health care organizations as possible
in our mission to improve patient safety and outcomes."

About Medasense

Medasense develops innovative medical devices and applications in
the field of physiological pain response monitoring. The NOL
(nociception Level Index) technology is based on proprietary signal
acquisition sensor platform, and advanced algorithms which identify
and grade the physiological pain response patterns. NOL® technology
enables clinicians to optimize pain control treatment and by that,
minimize adverse events, improve clinical outcomes and reduce costs.

- PMD-200 and its NOL index are not commercially available in the
U.S.

ots Originaltext: Medasense Biometrics Ltd
Im Internet recherchierbar: http://www.presseportal.de

Contact:
http://www.medasense.com ,info@medasense.com
Media Contact Details
Mira Sofer
VP Marketing and Business Development

Original-Content von: Medasense Biometrics Ltd, übermittelt durch news aktuell